---
company: RELMADA THERAPEUTICS, INC.
ticker: RLMD
form: 8-K
filed: 2026-08-06
accession: 0001213900-26-086190
source: https://www.sec.gov/Archives/edgar/data/1553643/000121390026086190/
---

# Relmada Therapeutics (RLMD) earnings release, August 6, 2026

Relmada Therapeutics, Inc. (RLMD) · Form 8-K, Item 2.02 · Filed 2026-08-06 · [SEC filing](https://www.sec.gov/Archives/edgar/data/1553643/000121390026086190/)

Relmada Therapeutics Reports Second Quarter

2026 Financial Results and Provides Business Update

CORAL GABLES, FL – August 6, 2026 (Globe

Newswire) – Relmada Therapeutics, Inc.

(Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today reported financial results for the second quarter ended June 30, 2026, and provided a business update.

“Relmada has entered a critical execution phase as we prepare NDV-01 for registrational development. With FDA alignment, a robust clinical dataset, an experienced leadership team, and capital expected to fund operations through completion of the Phase 3 RESCUE program, we believe the Company is well positioned to create significant long-term value,” said

Sergio Traversa, Chief Executive Officer of Relmada Therapeutics. “Our immediate priority is manufacturing execution for NDV-01. Bringing a novel, sustained-release therapy of this kind into registrational development requires careful execution, and we are focused on completing the remaining activities needed to support the IND filing.”

Manufacturing and CMC Update

The Company is advancing manufacturing and chemistry, manufacturing, and controls (CMC) activities to support planned IND filings for both NDV-01 and sepranolone by year-end 2026. Each program is progressing along its own development path.

NDV-01:

Manufacturing and CMC activities supporting the planned NDV-01 IND submission are ongoing. The Company expects to submit the NDV-01 IND by year-end 2026 and initiate the

Phase 3 RESCUE registrational program upon IND clearance. Clinical trial sites are engaged and prepared to begin enrollment following

IND clearance.

Sepranolone:

Formulation development for sepranolone is complete, and the Company is finalizing the pre-filled syringe delivery system. This is the remaining step ahead of the sepranolone IND submission, which is expected by year-end 2026. The company expects to initiate the Phase 2 proof-of-concept study in

Prader-Willi Syndrome following IND clearance.

Corporate Update

During the quarter, Relmada strengthened its leadership team with the appointment of Bipin Dalmia, PhD, MBA, as Chief Business Officer. He brings nearly three decades of biopharmaceutical leadership experience spanning business development, portfolio strategy, commercial planning, and uro-oncology, including leadership of the U.S. launch, indication expansion, global commercialization, and long-term manufacturing strategy for the first FDA-approved intravesical gene therapy for NMIBC.

“Since joining Relmada, I have become increasingly convinced that NDV-01 represents one of the most compelling opportunities in NMIBC,” said

Bipin Dalmia, Chief Business Officer of Relmada Therapeutics. “As the NMIBC treatment landscape continues to evolve, patients and physicians are seeking therapies that deliver meaningful efficacy and durability without compromising convenience, tolerability, or ease of use. As we advance toward registrational development, NDV-01’s highly differentiated profile and potential applicability across multiple patient populations position it to become a foundational and best-in-class intravesical therapy across the NMIBC disease spectrum.”

Expected Upcoming Relmada Milestones:

NDV-01:

Sepranolone:

Financial Results

Second Quarter 2026 Financial Results²

Conference Call and Webcast Information:

Relmada will host a conference call and webcast today at 4:30 PM ET to discuss recent business progress and financial results.

Conference Call and Webcast Information:

A replay of the webcast will be available in the

Investors section of the Relmada website at https://ir.relmada.com/investors/events/.

About NDV-01

NDV-01 is a novel, sustained-release, intravesical formulation of gemcitabine and docetaxel (Gem/Doce) being developed for the treatment of non-muscle invasive bladder cancer (NMIBC). The formulation is engineered to provide prolonged bladder retention and sustained drug release over approximately 10 days. By forming a soft intravesical matrix, NDV-01 is designed to increase local drug exposure while limiting systemic toxicity. The treatment can be administered conveniently in an office setting in under 5 minutes without the need for anesthesia or specialized equipment. NDV-01 is encompassed by multiple patent applications that if issued, could provide protection until 2047.

About the NDV-01 Phase 3 RESCUE Registrational Pathways:

Relmada has received written FDA feedback confirming alignment on two registrational development pathways for NDV-01, including study design, patient populations, and primary endpoints. The

Company expects to submit an IND by year-end 2026 and initiate the Phase 3 RESCUE program upon IND clearance.³

About NMIBC

NMIBC represents 75-80% of all bladder cancer cases and is associated with high recurrence rates (50 – 80% over 5 years) and disease progression in a subset of these patients.

With over 744,000 prevalent cases in the U.S. and limited treatment options, the market opportunity is significant. High-risk BCG-unresponsive disease represents the biggest unmet need in NMIBC, with limited and suboptimal bladder-sparing treatment options. Intermediate-risk NMIBC in the adjuvant setting has no currently approved therapies and patients with recurrence must undergo repeated surgical resections. NDV-01 has the potential to serve as a foundational frontline or salvage therapy across the NMIBC disease spectrum.

About Sepranolone and GABA Modulation

Sepranolone, a synthetic isoallopregnanolone, selectively modulates GABA

A receptors by antagonizing allopregnanolone (ALLO), without disrupting GABA signaling. It targets... (truncated)ss GABAergic activity such as Prader-Willi Syndrome (PWS), Tourette Syndrome, and Obsessive-Compulsive Disorder

(OCD). More than 335 patients have been treated with sepranolone in clinical trials to date, with an excellent safety profile. The Company expects to submit an IND by year-end 2026 and initiate the Phase 2 study in Prader-Willi syndrome upon IND clearance.

About Prader-Willi Syndrome (PWS)

PWS is a rare genetic disorder caused by chromosomal deletions on chromosome 15, leading to neurodevelopmental and behavioral complications. Global prevalence is estimated to be 350,000-400,000 patients. Current treatments address symptoms but do not modify the underlying neurobehavioral pathology.

About Relmada Therapeutics, Inc.

Relmada Therapeutics is a clinical-stage biotechnology company focused on developing transformative therapies for oncology and central nervous system conditions. Its lead candidates, NDV-01 and sepranolone, are advancing through clinical development with the potential to address significant unmet needs.

For more information, visit www.relmada.com⁴

Forward-Looking Statements:

The Private Securities Litigation Reform Act of

1995 provides a safe harbor for forward-looking statements made by us or on our behalf. This press release contains statements which constitute

“forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities

Exchange Act of 1934. Any statement that is not historical in nature is a forward-looking statement and may be identified by the use of words and phrases such as “if”, “may”, “expects”, “anticipates”, “believes”,

“will”, “will likely result”, “will continue”, “plans to”, “potential”, “promising”, and similar expressions. These statements are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including potential for Relmada’s product candidates to fail to progress, potential for Phase 2 NDV-01 data to fail to continue to deliver positive results supporting further development, potential for clinical trials to fail to deliver statistically and/or clinically significant evidence of efficacy and/or safety, failure of interim or top-line results to accurately reflect the complete results of the trial, failure of planned or ongoing preclinical and clinical studies to demonstrate expected results, potential failure to continue to secure FDA agreement on the regulatory path for NDV-01 and/or sepranolone, or that future NDV-01 and/or sepranolone clinical results will be acceptable to the FDA, failure to successfully execute manufacturing and CMC activities for NDV-01 and/or sepranolone, including GMP manufacture of clinical trial material, manufacturing scale-up, process validation, timing of completion of manufacturing activities, and regulatory acceptance of manufacturing-related submissions, failure to secure adequate NDV-01 and/or sepranolone drug supply, failure of pending patent applications to result in issued patents, or issued patents being challenged and invalidated by third parties or not providing us with any competitive advantages, the Company’s cash runway and sufficiency of the Company’s cash resources and uncertainties inherent in estimating the Company’s cash runway, future expenses and other financial results, including its ability to fund future operations, including clinical trials, and the other risk factors described under the heading “Risk Factors” set forth in the Company’s reports filed with the SEC from time to time. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Readers are cautioned that it is not possible to predict or identify all the risks, uncertainties and other factors that may affect future results and that the risks described herein are not a complete list.

Investor Contact:

Brian Ritchie

LifeSci Advisors britchie@lifesciadvisors.com

Media Inquiries:

Corporate Communications media@relmada.com⁵

Relmada Therapeutics, Inc.

Condensed Consolidated Balance Sheets⁶

Relmada Therapeutics, Inc.

Condensed Consolidated Statements of Operations

(Unaudited)⁷

Relmada Therapeutics, Inc.

Condensed Consolidated Statements of Stockholders’

Equity

(Unaudited)⁸

Relmada Therapeutics, Inc.

Condensed Consolidated Statements of Cash Flows

(Unaudited)⁹

## Financial statements

### Income Statement (Three months ended — (Unaudited))

| | Three months ended – June 30, – 2026 | Three months ended – June 30, – 2025 | Six months ended – June 30, – 2026 | Six months ended – June 30, – 2025 |
|---|---:|---:|---:|---:|
| Operating expenses: | Research and development | 8,393,789 | 2,819,377 | 16,481,634 | 14,770,400 |
| Operating expenses: | General and administrative | 6,617,238 | 7,401,929 | 17,991,147 | 13,669,342 |
| Operating expenses: | Total operating expenses | 15,011,027 | 10,221,306 | 34,472,781 | 28,439,742 |
| Operating expenses: | Loss from operations | -15,011,027 | -10,221,306 | -34,472,781 | -28,439,742 |
| Other (expenses) income: | Interest/investment income, net | 2,301,394 | 321,458 | 3,261,156 | 761,745 |
| Other (expenses) income: | Realized (loss) gain on short-term investments | -37,294 | 47,203 | -47,162 | 110,156 |
| Other (expenses) income: | Unrealized (loss) gain on short-term investments | -167,258 | -13,797 | -707,354 | 141,934 |
| Other (expenses) income: | Total other income | 2,096,842 | 354,864 | 2,506,640 | 1,013,835 |
| Other (expenses) income: | Net loss | -12,914,185 | -9,866,442 | -31,966,141 | -27,425,907 |
| Other (expenses) income: | Loss per common share – basic and diluted | -0.11 | -0.3 | -0.32 | -0.86 |
| Other (expenses) income: | Weighted average number of common shares outstanding – basic and diluted | 112,375,941 | 33,191,622 | 99,327,509 | 31,807,943 |

### Balance Sheet (Condensed Consolidated Balance Sheets)

| | As of – June 30, – 2026 (Unaudited) | As of – December 31, 2025 |
|---|---:|---:|
| Current assets: | Cash and cash equivalents | 11,334,370 | 3,496,540 |
| Current assets: | Short-term investments | 206,396,805 | 89,509,710 |
| Current assets: | Other receivable | 10,912 |  |
| Current assets: | Prepaid expenses | 1,297,590 | 977,721 |
| Current assets: | Total current assets | 219,039,677 | 93,983,971 |
| Current assets: | Other assets | 19,500 | 19,500 |
| Current assets: | Total assets | 219,059,177 | 94,003,471 |
| Current liabilities: | Accounts payable | 2,409,190 | 1,568,944 |
| Current liabilities: | Accrued expenses | 5,011,583 | 4,861,583 |
| Current liabilities: | Total current liabilities | 7,420,773 | 6,430,527 |
| Current liabilities: | Stock appreciation rights | 5,080,081 | 1,060,931 |
| Current liabilities: | Total liabilities | 12,500,854 | 7,491,458 |
| Stockholders’ Equity: | Common stock, $0.001 par value, 200,000,000 shares authorized, 106,669,846 and 73,333,622 shares issued and outstanding, respectively | 106,670 | 73,333 |
| Stockholders’ Equity: | Additional paid-in capital | 936,684,992 | 784,705,878 |
| Stockholders’ Equity: | Accumulated deficit | -730,233,339 | -698,267,198 |
| Stockholders’ Equity: | Total stockholders’ equity | 206,558,323 | 86,512,013 |
| Stockholders’ Equity: | Total liabilities and stockholders’ equity | 219,059,177 | 94,003,471 |

### Cash Flow (Six months ended June 30, — Condensed Consolidated Statements of Cash Flows (Unaudited))

| | Six months ended June 30, – 2026 | Six months ended June 30, – 2025 |
|---|---:|---:|
| Cash flows from operating activities | Net loss | -31,966,141 | -27,425,907 |
| Adjustments to reconcile net loss to net cash used in operating activities: | Stock-based compensation | 1,859,089 | 7,021,222 |
| Adjustments to reconcile net loss to net cash used in operating activities: | Stock appreciation rights compensation | 4,019,150 | 27,649 |
| Adjustments to reconcile net loss to net cash used in operating activities: | Issuance of restricted common stock |  | 905,226 |
| Adjustments to reconcile net loss to net cash used in operating activities: | Realized loss/(gain) on short-term investments | 47,162 | -110,156 |
| Adjustments to reconcile net loss to net cash used in operating activities: | Unrealized loss/(gain) on short-term investments | 707,354 | -141,934 |
| Change in operating assets and liabilities: | Prepaid expenses and other assets | -319,869 | 411,834 |
| Change in operating assets and liabilities: | Accounts payable | 840,246 | -2,768,652 |
| Change in operating assets and liabilities: | Accrued expenses | 150,000 | -2,388,191 |
| Change in operating assets and liabilities: | Other receivable | -10,912 |  |
| Change in operating assets and liabilities: | Net cash used in operating activities | -24,673,921 | -24,468,909 |
| Cash flows from investing activities | Purchase of short-term investments | -174,270,466 | -809,375 |
| Cash flows from investing activities | Sale of short-term investments | 56,628,855 | 22,847,630 |
| Cash flows from investing activities | Net cash (used in)/provided by investing activities | -117,641,611 | 22,038,255 |
| Cash flows from financing activities | Proceeds from issuance of common stock | 159,999,996 |  |
| Cash flows from financing activities | Payment of fees for issuance of common stock | -9,817,890 |  |
| Cash flows from financing activities | Proceeds from options exercised for common stock | 101,497 |  |
| Cash flows from financing activities | Proceeds from warrants exercised for common stock | 1,683 |  |
| Cash flows from financing activities | ATM fees | -131,924 | -73,021 |
| Cash flows from financing activities | Net cash provided/(used in) by financing activities | 150,153,362 | -73,021 |
| Cash flows from financing activities | Net increase/(decrease) in cash and cash equivalents | 7,837,830 | -2,503,675 |
| Cash flows from financing activities | Cash and cash equivalents at beginning of the period | 3,496,540 | 3,857,026 |
| Cash flows from financing activities | Cash and cash equivalents at end of the period | 11,334,370 | 1,353,351 |
| Non-cash investing and financing activities | Cashless exercise of warrants for common stock | -2,082 |  |
